Pfizer’s stock has underperformed lately, falling 4.6% while still doing marginally better than its peers. Analysts have made ...

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Representative Rob Bresnahan, Jr. of Pennsylvania recently made headlines—not for legislation, but for investing between ...

While tariffs have triggered market volatility, certain pharmaceutical stocks still present strong investment opportunities.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

(Reuters) -Pfizer Inc plans to tap the mRNA technology to make new vaccines for other viruses following the success of its ...

U.S. stock futures declined Sunday after Treasury Secretary Scott Bessent said he’s not worried about a market downturn, despite a miserable stretch for Wall Street. “I’ve been in the ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

In a filing disclosed on March 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Pfizer stock on February ... As a group, analysts forecast that Pfizer Inc ...

The most recent trading session ended with Pfizer (PFE) standing at $25.60, reflecting a -0.43% shift from the previouse trading day's closing. This change was narrower than the S&P 500's daily loss ...

The most recent trading session ended with Pfizer (PFE ... alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank ...